In June 2018, OIG published a data brief Increases in Reimbursement for Brand-Name Drugs in Part D (OEI-03-15-00080). This data brief found that even after accounting for rebates, Part D reimbursement for brand-name drugs increased 62 percent from 2011 to 2015. Subsequently, OIG received a Congressional request to provide more information about brand name drugs with Part D reimbursement and rebates in every year from 2011 to 2015.
Friday, September 13, 2019
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
Component, if applicable:
Centers for Medicare & Medicaid Services
Type of Report:
Inspection / Evaluation